Gufic Biosciences (509079) Q4 25/26 earnings summary

Executive summary

• Audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, were approved, showing continued profitability and growth in revenue and net profit year-over-year.

• Board recommended a final dividend of Re. 0.10 per equity share (10% of face value) for FY 2025-26, subject to shareholder approval.

• Appointment of new internal auditor and re-appointment of cost auditor for FY 2026-27.

• Further investment of Rs. 5.75 crore in Saraswat Co-operative Bank Ltd. to strengthen banking relationships and treasury management.

• Amendment to the Code of Conduct for Directors and Senior Management to align with updated regulations.

Financial highlights

• Consolidated revenue from operations for FY 2025-26 was Rs. 94,400.66 lakhs, up from Rs. 81,980.59 lakhs year-over-year.

• Consolidated net profit for FY 2025-26 was Rs. 6,421.27 lakhs, compared to Rs. 6,964.87 lakhs in the previous year.

• Q4 FY 2025-26 consolidated net profit was Rs. 2,189.61 lakhs, up from Rs. 1,242.36 lakhs in Q3 FY 2025-26.

• Basic and diluted EPS for FY 2025-26 stood at Rs. 6.40 and Rs. 6.95, respectively.

• Cash and cash equivalents at year-end increased to Rs. 6,218.59 lakhs from Rs. 1,572.33 lakhs year-over-year.

Outlook and guidance

• The company expects strengthened banking relationships and improved treasury management following the investment in Saraswat Bank.

• Dividend payout reflects confidence in ongoing profitability and cash flow generation.